Sherlock Biosciences
Sherlock Biosciences Raises $220M in Series C
Quick Facts
Sherlock Biosciences Raises $220M in Series C
Sherlock Biosciences has successfully raised $220M in a Series C at a $1.5B valuation led by Vivo Capital, Baillie Gifford, GV, Taiho Ventures, Perceptive Advisors, William K. Warren Foundation.
Company Overview
Sherlock Biosciences is a Biotech company headquartered in 201 Brookline Avenue, Boston, MA 02215, founded in 2019 with 150+ employees.
CRISPR-powered diagnostics
Fundraising Details
- Amount Raised: $220M
- Round Type: Series C
- Valuation: $1.5B
- Date: 2024-01-08
- Investors: Vivo Capital, Baillie Gifford, GV, Taiho Ventures, Perceptive Advisors, William K. Warren Foundation
About Sherlock Biosciences
CRISPR-powered diagnostics The company is positioned in the Biotech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: 201 Brookline Avenue, Boston, MA 02215
- Founded: 2019
- Team Size: 150+
- Industry: Biotech
What This Means
This funding round demonstrates strong investor confidence in Sherlock Biosciences's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Sherlock Biosciences's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $1.5B valuation marks an important milestone for Sherlock Biosciences, positioning the company among notable players in the Biotech industry.
Looking Ahead
With this new capital, Sherlock Biosciences is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2024-01-08. For more information about Sherlock Biosciences, visit their headquarters at 201 Brookline Avenue, Boston, MA 02215.
About the Author
Related Company Reports
Beacon Software Raises $250M in Series B
Beacon Software, a SaaS company based in San Francisco, CA, has raised $250M in Series B at a $1B valuation led by Riverwood Capital, Norwest Venture Partners.
The Every Company Raises $55M in Series D
The Every Company, a FoodTech company based in San Francisco, CA, has raised $55M in Series D led by Temasek, Section 32, SOSV.
Anrok Raises $55M in Series C
Anrok, a FinTech company based in San Francisco, CA, has raised $55M in Series C led by Sequoia Capital, Index Ventures, Felicis.